OptiNose Market Cap ($97.22 Million)
Market Cap & Net Worth: OptiNose (OPTN)
OptiNose market cap. OptiNose (NASDAQ:OPTN) has a market capitalization of $97.22 Million ($97.22 Million) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19168 globally and #4426 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OptiNose's stock price $9.60 by its total outstanding shares 10127400 (10.13 Million).
OptiNose Market Cap History (2017–2025)
OptiNose market cap history from 2017 to 2025. Data shows change from $191.41 Million to $97.22 Million (-8.59% CAGR). Check today's stock price for OptiNose for real-time trading data and today's change.
Index Memberships
OptiNose is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #536 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.00% | #1836 of 3165 |
Weight: OptiNose's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
OptiNose Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OptiNose's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see OptiNose operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.86x
OptiNose's market cap is 0.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $191.41 Million | $162.00K | -$48.90 Million | 1181.53x | N/A |
| 2018 | $62.79 Million | $7.07 Million | -$106.66 Million | 8.89x | N/A |
| 2019 | $93.37 Million | $34.63 Million | -$108.94 Million | 2.70x | N/A |
| 2020 | $41.93 Million | $49.12 Million | -$98.33 Million | 0.85x | N/A |
| 2021 | $16.41 Million | $74.65 Million | -$81.65 Million | 0.22x | N/A |
| 2022 | $18.74 Million | $76.28 Million | -$76.39 Million | 0.25x | N/A |
| 2023 | $13.06 Million | $70.99 Million | -$35.48 Million | 0.18x | N/A |
| 2024 | $67.65 Million | $78.23 Million | -$21.54 Million | 0.86x | N/A |
Competitor Companies of OPTN by Market Capitalization
Companies near OptiNose in the global market cap rankings as of October 31, 2026. See debt-free asset ratio of OptiNose to understand what proportion of total assets are financed by equity.
Key companies related to OptiNose by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #600 globally with a market cap of $45.38 Billion USD ( CN¥310.15 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.98 |
| #600 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.38 Billion | CN¥48.62 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €17.90 |
Market Capitalization of OptiNose (2017–2025)
Market capitalization of OptiNose from 2017 to today. Between 2017 and today, OptiNose's market cap moved from $191.41 Million to $ 97.22 Million, with a yearly change of -8.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $97.22 Million | +43.71% |
| 2024 | $67.65 Million | +417.83% |
| 2023 | $13.06 Million | -30.27% |
| 2022 | $18.74 Million | +14.20% |
| 2021 | $16.41 Million | -60.87% |
| 2020 | $41.93 Million | -55.10% |
| 2019 | $93.37 Million | +48.71% |
| 2018 | $62.79 Million | -67.20% |
| 2017 | $191.41 Million | -- |
End of Day Market Cap According to Different Sources
On May 19th, 2026 the market cap of OptiNose was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $97.22 Million USD |
| MoneyControl | $97.22 Million USD |
| MarketWatch | $97.22 Million USD |
| marketcap.company | $97.22 Million USD |
| Reuters | $97.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well … Read more